{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:46:28Z","timestamp":1761007588104,"version":"build-2065373602"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,7,18]],"date-time":"2002-07-18T00:00:00Z","timestamp":1026950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2002,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abrupt clozapine withdrawal can cause rebound psychosis and severe somatic symptoms in psychiatric patients. We report on the case of an advanced Parkinson's disease patient who developed myoclonus, tremor, rigidity, hyperreflexia, and stupor after abrupt clozapine withdrawal. The patient's symptoms resolved with treatment with cyproheptadine. This clinical picture suggests serotonergic rebound as an explanation for the patient's symptoms, although other pharmacological mechanisms are possible. Clozapine should be gradually withdrawn over a period of 1 to 2 weeks when possible, and abruptly discontinued only when necessary. \u00a9 2002 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.10282","type":"journal-article","created":{"date-parts":[[2002,12,4]],"date-time":"2002-12-04T09:20:29Z","timestamp":1038993629000},"page":"1365-1367","source":"Crossref","is-referenced-by-count":16,"title":["Clozapine withdrawal symptoms in a Parkinson's disease patient"],"prefix":"10.1002","volume":"17","author":[{"given":"Theresa A.","family":"Zesiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujatha","family":"Borra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,7,18]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00860-0"},{"key":"e_1_2_4_3_2","first-page":"122","article-title":"Withdrawal from clozapine: the \u201crebound phenomenon\u201d","volume":"36","author":"Durst R","year":"1999","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120403"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950240089014"},{"first-page":"2155","volume-title":"Physician's Desk Reference","year":"2001","key":"e_1_2_4_7_2"},{"key":"e_1_2_4_8_2","first-page":"522","article-title":"Neuroleptic malignant syndrome associated with long\u2010term clozapine treatment: report of a case and results of a clozapine rechallenge","volume":"24","author":"Huang TL","year":"2001","journal-title":"Chang Gung Med J"},{"key":"e_1_2_4_9_2","first-page":"168","article-title":"Neuroleptic malignant syndrome related to use of clozapine","volume":"98","author":"Trayer JS","year":"1998","journal-title":"J Am Osteopath Assoc"},{"key":"e_1_2_4_10_2","first-page":"329","article-title":"Clozapine: guidelines for clinical management","volume":"50","author":"Lieberman JA","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/21.2.333"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199910000-00007"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/22.4.591"},{"key":"e_1_2_4_14_2","first-page":"119","article-title":"Anticholinergics to treat clozapine withdrawal","volume":"55","author":"de Leon J","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0603"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0906"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245619"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02274897"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830200095014"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830200094013"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00464798"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431719"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00690943"},{"key":"e_1_2_4_24_2","first-page":"346","article-title":"Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study","volume":"52","author":"Alphs LK","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199304000-00012"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130302"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200005)15:3<579::AID-MDS1024>3.0.CO;2-0"},{"key":"e_1_2_4_29_2","first-page":"679","article-title":"Clozapine: A new antipsychotic agent","volume":"16","author":"Simpson GM","year":"1974","journal-title":"Curr Ther Res"},{"key":"e_1_2_4_30_2","unstructured":"DanielDG GoldbergT WeinbergerDR et al.Clozapine Versus Risperidone in Psychosis. Presented at the Annual Meeting of the Society of Biological Psychiatry. Philadelphia PA May1994."},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050901"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199504050-00004"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.137.1.16"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00215-4"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.2.249"},{"key":"e_1_2_4_36_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/070674376601101S27","article-title":"Withdrawal symptoms after abrupt termination of imipramine","volume":"2","author":"Shatan C","year":"1966","journal-title":"Can Psychiatric Association J"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.123.2.221"},{"key":"e_1_2_4_38_2","first-page":"410","article-title":"Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic inpatients","volume":"11","author":"Melnyk WT","year":"1966","journal-title":"Am J Psychiatry"},{"key":"e_1_2_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(89)90027-1"},{"key":"e_1_2_4_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410133311514"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10282","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.10282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:25:09Z","timestamp":1760970309000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.10282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,18]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["10.1002\/mds.10282"],"URL":"https:\/\/doi.org\/10.1002\/mds.10282","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2002,7,18]]}}}